E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

  • Law Blogs

Become a Fan

« Gene Patenting Debate Continues - Round Two | Main | Exergen Corp. v. Wal-Mart Stores, Inc. (Fed. Cir. 2009) »

August 05, 2009

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d83451ca1469e20120a5234a1a970c

Listed below are links to weblogs that reference Follow-on Biologics News Briefs - No. 7:

Comments

One way to reduce cost on prescription drug prices is to offer a modified patent arrangement to prescription drug vendors in exchange for a negotiated lower price for the prescriptions.

Drug manufacturers charge exorbitant prices because patents only last 7 years and they need to make as much as possible during the patent period in order to cover the cost of R&D. The federal government should offer a modified arrangement to the prescription drug companies.

Drug manufactures should be offered the option to retain patents for longer periods if they agree to reduce pricing during the length of the patent.

This option will result in lower cost and a better business model for prescription drug companies. It is a win-win for the manufacturers, insurance companies and the patient.

The comments to this entry are closed.

October 2014

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31